Vicapsys Life Sciences, Inc. (OTCMKTS:VICP – Get Free Report) shares traded down 58.3% on Tuesday . The company traded as low as $1.25 and last traded at $1.25. 500 shares traded hands during trading, an increase of 32% from the average session volume of 380 shares. The stock had previously closed at $3.00.
Vicapsys Life Sciences Stock Performance
The company has a market cap of $40.46 million, a price-to-earnings ratio of -31.25 and a beta of -3.93. The company’s 50 day moving average price is $1.75 and its 200-day moving average price is $2.03.
Vicapsys Life Sciences (OTCMKTS:VICP – Get Free Report) last issued its quarterly earnings results on Friday, January 10th. The company reported ($0.01) EPS for the quarter.
About Vicapsys Life Sciences
Vicapsys Life Sciences, Inc focuses on the development and commercialization of VICAPSYN, a proprietary product. The company’s product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers.
Read More
- Five stocks we like better than Vicapsys Life Sciences
- EV Stocks and How to Profit from Them
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- Energy and Oil Stocks Explained
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- What is a Special Dividend?
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Vicapsys Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicapsys Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
